<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04327024</url>
  </required_header>
  <id_info>
    <org_study_id>D5496C00005</org_study_id>
    <secondary_id>2019-004862-16</secondary_id>
    <nct_id>NCT04327024</nct_id>
  </id_info>
  <brief_title>Study of Verinurad in Heart Failure With Preserved Ejection Fraction</brief_title>
  <acronym>AMETHYST</acronym>
  <official_title>A Phase 2, Multicentre, Double-Blind, Placebo and Active Control Efficacy and Safety Study to Evaluate Verinurad Combined With Allopurinol in Heart Failure With Preserved Ejection Fraction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      International, Multicenter, Double-Blind, Placebo and Active Control Efficacy and Safety&#xD;
      Study to Evaluate Verinurad combined with Allopurinol in Heart Failure with Preserved&#xD;
      Ejection Fraction&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Evidence shows independent associations between hyperuricaemia and the risk of cardio-renal&#xD;
      conditions, including heart failure (HF). Serum uric acid (sUA) is also a strong prognostic&#xD;
      factor and correlates with other markers of poor prognosis in HF patients with preserved&#xD;
      ejection fraction (HFpEF), and an estimated 1/2-2/3 of HFpEF patients have hyperuricaemia.&#xD;
      HFpEF is a microvascular disease likely partly driven by endothelial dysfunction and&#xD;
      inflammation in coronary vessel walls. Uric acid crystals have been identified in coronary&#xD;
      vessel walls in some hyperuricaemic patients.&#xD;
&#xD;
      Uric acid transporter 1 (URAT1) is responsible for reabsorption of uric acid (UA) in the&#xD;
      proximal tubule. Inhibition of URAT1 results in increased urinary excretion of UA and&#xD;
      lowering of uric acid in the blood. Verinurad is a novel URAT1 inhibitor in Phase 2&#xD;
      development for chronic kidney disease (CKD) and HF. Verinurad combined with the xanthine&#xD;
      oxidase (XO) inhibitors (XOI) febuxostat or allopurinol has been shown to lower sUA in&#xD;
      patients with recurrent gout in Phase 2 studies by up to approximately 80%.&#xD;
&#xD;
      The primary objective of this Phase 2 study is to assess the effect of a combination of&#xD;
      verinurad and allopurinol on exercise capacity in patients with HFpEF.&#xD;
&#xD;
      The secondary objectives are to assess effect of combination of verinurad and allopurinol in&#xD;
      comparison to allopurinol monotheraphy on excercise capacity dwhich will be measured in peak&#xD;
      VO2 as well as effect of verinurad and allopurinol compared to placebo and to allopurinol&#xD;
      monotheraphy on Kansas City cardiomyopathy questionnaire (KCCQ)-total symptom score (TSS). A&#xD;
      sub-study aims to investigate the relationship between UA crystals and inflammation.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">May 19, 2020</start_date>
  <completion_date type="Anticipated">April 29, 2022</completion_date>
  <primary_completion_date type="Anticipated">April 29, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline at Week 32 in peak V02</measure>
    <time_frame>From baseline at Week 32</time_frame>
    <description>To assess effect of verinurad + allopurinol compared to placebo or allopurinol monotherapy on exercise capacity.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline at Week 32 in Kansas-City Cardiomyopathy Questionnaire-Total Symptom Score (KCCQ-TSS)</measure>
    <time_frame>From baseline at Week 32</time_frame>
    <description>To assess effect of verinurad + allopurinol compared to placebo or allopurinol monotherapy on Kansas-City Cardiomyopathy Questionnaire-Total Symptom Score (KCCQ-TSS). The score ranges from 0 to 100, where a higher score represents a better patient outcome.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">159</enrollment>
  <condition>Heart Failure With Preserved Ejection Fraction (HFpEF)</condition>
  <arm_group>
    <arm_group_label>Verinurad 12 + allopurinol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose [mg] verinurad/allopurinol:&#xD;
Step 1 - titration_3/100 Step 2 - titration_7.5/200 Step 3 - target dose 12/300</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Allopurinol alone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose [mg] verinurad/allopurinol:&#xD;
Step 1 - titration_0/100 Step 2 - titration_0/200 Step 3 - target dose 0/300</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo [mg] in 3 steps 0/0</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Verinurad</intervention_name>
    <description>The treatment will be titrated in 3 steps for target low dose (3 mg), intermediate dose (7.5 mg) and high dose (12mg) of verinurad.&#xD;
Drug: Allopurinol The treatment will be titrated in 3 steps. Low dose (100mg), intermediate (200mg) and high dose (300mg) of allopurinol.</description>
    <arm_group_label>Verinurad 12 + allopurinol</arm_group_label>
    <other_name>verinurad titration 3 - 7.5 - 12mg</other_name>
    <other_name>allopurinol titration 100 - 200 - 300 mg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Allopurinol</intervention_name>
    <description>Study treatments will be titrated in 3 steps: Low dose (100mg), intermediate (200mg) and high dose (300mg) of allopurinol</description>
    <arm_group_label>Allopurinol alone</arm_group_label>
    <arm_group_label>Verinurad 12 + allopurinol</arm_group_label>
    <other_name>allopurinol titration 100 - 200 - 300 mg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo for verinurad</intervention_name>
    <description>Matching Capsule</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Placebo</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo for allopurinol</intervention_name>
    <description>Matching tablet</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient must be ≥ 40 years of age at the time of signing the ICF&#xD;
&#xD;
          -  Patients with hyperuricaemia defined as sUA level of &gt; 6 mg/dL.&#xD;
&#xD;
          -  Patients with documented diagnosis of symptomatic HFpEF according to all of the&#xD;
             following criteria:&#xD;
&#xD;
               1. Have NYHA functional class II-III at enrolment&#xD;
&#xD;
               2. Have medical history of typical symptoms/signs of HF &gt; 6 weeks before enrolment&#xD;
&#xD;
               3. LVEF ≥ 45%&#xD;
&#xD;
               4. NT-proBNP ≥ 125 pg/mL (≥ 14.75 pmol/L) at Visit 1 for patients without ongoing&#xD;
                  atrial fibrillation/flutter.&#xD;
&#xD;
          -  Patients able to exercise to near exhaustion during a CPET as exhibited by RER&#xD;
&#xD;
             ≥ 1.05 during CPET conducted during screening. If patient does not achieve RER ≥ 1.05&#xD;
             the CPET may be repeated once, at least 48 hours but less than 2 weeks (but before&#xD;
             randomisation) after the initial test; in such cases the second test will serve as&#xD;
             baseline.&#xD;
&#xD;
          -  Male or female&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  eGFR &lt; 30ml/min/1.73m2 (based on CKD-EPI formula)&#xD;
&#xD;
          -  Presence of any condition that precludes exercise testing&#xD;
&#xD;
          -  Known history of a documented LVEF &lt; 40%&#xD;
&#xD;
          -  Probable alternative or concomitant diagnoses which in the opinion of the Investigator&#xD;
             could account for the patient's HF symptoms and signs (eg, anaemia, hypothyroidism)&#xD;
&#xD;
          -  Known carrier of the Human Leukocyte Antigen-B (HLA-B) *58:01 allele: HLA-B&#xD;
&#xD;
             *58:01 genotyping is mandatory prior to randomization for all patients.&#xD;
&#xD;
          -  Patients diagnosed with tumor lysis syndrome or Lesch-Nyhan syndrome&#xD;
&#xD;
          -  Patients who are severely physically or mentally incapacitated and who in the opinion&#xD;
             of investigator are unable to perform the patients' tasks associated with the protocol&#xD;
&#xD;
          -  Presence of any condition which, in the opinion of the investigator, places the&#xD;
             patient at undue risk or potentially jeopardises the quality of the data to be&#xD;
             generated&#xD;
&#xD;
          -  Current acute decompensated HF or hospitalisation due to decompensated HF &lt; 4 weeks&#xD;
             prior to enrolment&#xD;
&#xD;
          -  Myocardial infarction, unstable angina, coronary revascularisation (percutaneous&#xD;
             coronary intervention or coronary artery bypass grafting), ablation of atrial&#xD;
             flutter/fibrillation, valve repair/replacement, implantation of a cardiac&#xD;
             resynchronisation therapy device, stroke or transient ischemic attack within 6 months&#xD;
             prior to enrolment.&#xD;
&#xD;
          -  Planned coronary revascularisation, ablation of atrial flutter/fibrillation and/or&#xD;
             valve repair/replacement&#xD;
&#xD;
          -  Atrial fibrillation with persistent resting heart rate &gt; 110 beats per minute.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>130 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dalane Kitzman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>1326 Riverview Road Ext Lexington, NC 27292-1764 USA</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Granada Hills</city>
        <state>California</state>
        <zip>91344</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Northridge</city>
        <state>California</state>
        <zip>91324</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Torrance</city>
        <state>California</state>
        <zip>90502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33135</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Pembroke Pines</city>
        <state>Florida</state>
        <zip>33024</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Port Orange</city>
        <state>Florida</state>
        <zip>32127</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23510</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Caba</city>
        <zip>C1119ACN</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Caba</city>
        <zip>C1425AGC</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Caba</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Mar del Plata</city>
        <zip>7600</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Mar del Plata</city>
        <zip>B7600GNY</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Rosario</city>
        <zip>2000</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bedford Park</city>
        <zip>5042</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Chermside</city>
        <zip>4032</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Geelong</city>
        <zip>3220</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Milton</city>
        <zip>4064</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Graz</city>
        <zip>8036</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Wien</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Plovdiv</city>
        <zip>4004</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sofia</city>
        <zip>1000</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sofia</city>
        <zip>1431</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Quebec</city>
        <zip>G1G 3Y8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Quebec</city>
        <zip>G1V 4G5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Quebec</city>
        <zip>G2J 0C4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Quebec</city>
        <zip>G3K 2P8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bad Oeynhausen</city>
        <zip>32545</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Berlin</city>
        <zip>10789</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Berlin</city>
        <zip>D-13353</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Goettingen</city>
        <zip>37075</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Regensburg</city>
        <zip>93053</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Würzburg</city>
        <zip>97078</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Cheongju-si</city>
        <zip>28644</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Gangwon-do</city>
        <zip>26426</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Seoul</city>
        <zip>03080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Seoul</city>
        <zip>03722</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Seoul</city>
        <zip>05505</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Seoul</city>
        <zip>08308</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Querétaro</city>
        <zip>76000</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bydgoszcz</city>
        <zip>85-079</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Chojnice</city>
        <zip>89-600</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Chrzanów</city>
        <zip>32-500</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lublin</city>
        <zip>20-362</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tychy</city>
        <zip>43-100</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Warszawa</city>
        <zip>02-097</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Warszawa</city>
        <zip>02-637</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Warszawa</city>
        <zip>04-628</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Aramil</city>
        <zip>624002</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kemerovo</city>
        <zip>650002</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Novosibirsk</city>
        <zip>630055</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Saint-Petersburg</city>
        <zip>199226</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>St Petersburg</city>
        <zip>195067</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tomsk</city>
        <zip>634012</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Brezno</city>
        <zip>97742</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lucenec</city>
        <zip>984 01</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Presov</city>
        <zip>080 01</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Svidnik</city>
        <zip>08901</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Australia</country>
    <country>Austria</country>
    <country>Bulgaria</country>
    <country>Canada</country>
    <country>Germany</country>
    <country>Korea, Republic of</country>
    <country>Mexico</country>
    <country>Poland</country>
    <country>Russian Federation</country>
    <country>Slovakia</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Hong Kong</country>
  </removed_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>March 13, 2020</study_first_submitted>
  <study_first_submitted_qc>March 27, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 30, 2020</study_first_posted>
  <last_update_submitted>November 7, 2021</last_update_submitted>
  <last_update_submitted_qc>November 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Phase 2,</keyword>
  <keyword>Double-Blind,</keyword>
  <keyword>Placebo and Active Control,</keyword>
  <keyword>Verinurad,</keyword>
  <keyword>Allopurinol,</keyword>
  <keyword>HFpEF,</keyword>
  <keyword>Heart Failure</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Allopurinol</mesh_term>
    <mesh_term>Verinurad</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.&#xD;
Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_time_frame>AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.</ipd_time_frame>
    <ipd_access_criteria>When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.</ipd_access_criteria>
    <ipd_url>https://astrazenecagroup-dt.pharmacm.com/DT/Home</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

